logo
Plus   Neg
Share
Email

AstraZeneca: Imfinzi Shows Improved, Durable Responses In Extensive-stage SCLC

AstraZeneca (AZN.L,AZN) said Imfinzi (durvalumab) significantly improved overall survival in patients with previously-untreated extensive-stage small cell lung cancer. The detailed results from the Phase III CASPIAN trial were presented at the Presidential Symposium of the IASLC 2019 World Conference on Lung Cancer. The safety and tolerability of Imfinzi in combination with SoC etoposide and platinum-based chemotherapy was consistent with prior trials.

Jose´ Baselga, Executive Vice President, Oncology R&D said: "We are encouraged to see more than a third of small cell lung cancer patients treated with Imfinzi plus chemotherapy alive at the 18-month landmark, which is remarkable given the aggressive nature of the disease."

Imfinzi is approved in the curative-intent setting of unresectable, Stage III non-small cell lung cancer after chemoradiotherapy in 49 countries.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apotex Corp. recalled all lots of type 2 diabetes medication Metformin hydrochloride in the form of oral film-coated tablets for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Groupe Renault plans to cut about 14,600 jobs across the world and lower its production capacity. The plan includes almost 4,600 jobs reduction in France, through voluntary retirement and retraining. Amazon said it will convert 125,000 of the 175,000 temporary workers it hired in March amid the coronavirus pandemic, to permanent full-time employees in June. The e-commerce giant had hired the temporary employees in March to meet strong consumer demand amid the lockdown. The job openings were in Amazon's fulfillment centers and its delivery network.
Follow RTT